These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33565320)

  • 21. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipids: a personal view of the past decade.
    Katsiki N; Mikhailidis DP
    Hormones (Athens); 2018 Dec; 17(4):461-478. PubMed ID: 30229482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
    Agrawal S; Zaritsky JJ; Fornoni A; Smoyer WE
    Nat Rev Nephrol; 2018 Jan; 14(1):57-70. PubMed ID: 29176657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Not Available].
    Bilz S
    Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipid-Modifying Drugs: Pharmacology and Perspectives.
    Xu RX; Wu YJ
    Adv Exp Med Biol; 2020; 1177():133-148. PubMed ID: 32246446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Update: clinical lipidology].
    Parhofer KG
    MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
    Katsiki N; Mikhailidis DP; Banach M
    Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
    [No Abstract]   [Full Text] [Related]  

  • 31. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine.
    van der Laarse A; Cobbaert CM
    Expert Rev Cardiovasc Ther; 2021 Dec; 19(12):1085-1096. PubMed ID: 34937476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with statins and omega-3 fatty acids.
    Nambi V; Ballantyne CM
    Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive LDL-cholesterol lowering therapy and neurocognitive function.
    Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D
    Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PERSONALIZED APPROACH TO LIPID-LOWERING THERAPY].
    Scheen AJ; Descamps OS
    Rev Med Liege; 2015; 70(5-6):292-8. PubMed ID: 26285455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inter-Individual Variability in Lipid Response: A Narrative Review.
    Patnaik S; Pollevick ME; Lara-Breitinger KM; Stone NJ
    Am J Med; 2022 Dec; 135(12):1427-1433.e7. PubMed ID: 35878687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.